In human medicine, management of CKD‐MBD utilizes an integrated approach, including dietary phosphate restriction and oral phosphate binders (to reduce intestinal phosphate absorption), calcimimetics (to lower PTH by enhancing activation of the calcium‐sensing receptor), and vitamin D sterols (to increase intestinal calcium absorption and to inhibit PTH genomic synthesis and secretion).12 This evidence concerns the gene PTH and Marchiafava-Bignami disease.